HKU Scholars Hub: Browsing DSpace

Browsing by Author Hou, HA

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 4 of 4

	Title	Author(s)	Issue Date
	Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis Proceeding/Conference:Blood	Gill, H AU, LSS Yim, RLH Chin, ZL Li, WKV Lee, P Leung, GMK Lee, C Wu, TKY Ngai, C Ho, R Sin, CF Hou, HA Chen, CC Kwong, YL	2022
	MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia Proceeding/Conference:Clinical Lymphoma Myeloma and Leukemia	Mesa, R Komatsu, N Singh, GHH Jin, J Lee, SE Hou, HA Sato, T Qin, A Urbanski, R Shih, W Oleh, Z Craig, C Verstovsek, S	2022
	Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia Proceeding/Conference:Blood	Mesa, RA Komatsu, N Singh, GHH Jin, J Lee, SE Hou, HA Sato, T Qin, A Urbanski, R Shih, W Zagrijtschuk, C Zimmerman, C Verstovsek, S	2021
	SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia Journal:Future Oncology	Verstovsek, S Komatsu, N Singh, GHH Jin, J Lee, SE Hou, HA Sato, T Qin, A Urbanski, R Shih, W Zagrijtschuk, O Zimmerman, C Mesa, RA	2022

Showing results 1 to 4 of 4